Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
First nine months 2020 results presentation
Operating income, growth figures, profitability and how our products have behaved.
Thu, 05/11/2020 - 00:00
0 min
Español
6S3A6968(3).jpg
Download related document
Select rating
Give First nine months 2020 results presentation 1/5
Give First nine months 2020 results presentation 2/5
Give First nine months 2020 results presentation 3/5
Give First nine months 2020 results presentation 4/5
Give First nine months 2020 results presentation 5/5
No votes yet
Related
First nine months 2022 results press release
ROVI reports operating revenue growth of 24% and EBITDA growth of 25% • Operating revenue increased by 24% to 575.5 million euros driven...
3 min
04/11/2022
The President of the Andalusian Government, Juan Manel Moreno, visits the new...
On his visit to the plant, which is ready to start production as soon as the authorisation from the Spanish Agency of Medicines and...
4 min
24/10/2022
Glicopepton Biotech founded to produce compounds of high technological value
Glicopepton Biotech founded to produce compounds of high technological value · ROVI, Càrniques Celrà and Grupo Costa announce...
3 min
04/10/2022
See More
Email
Facebook
Twitter
LinkedIn
6S3A6968(3).jpg